安科生物(300009.SZ):2019年淨利預降35.40%-54.40%
格隆匯1月20日丨安科生物(300009.SZ)披露2019年年度業績預告,預計2019年1-12月歸屬於上市公司股東的淨利潤為1.2億元-1.7億元,同比下降54.40%-35.40%;預計2019年1-12月歸屬於上市公司股東的淨利潤(未計提商譽和無形資產減值準備)為3.2億元-3.7億元,同比增長21.59%-40.59%。業績變動原因及説明:
1、報告期內,公司加大市場推廣力度,主營產品重組人生長激素繼續保持較高的增長,公司其他生物製品、中成藥品等產品的銷售收入繼續保持穩定增長。
2、中德美聯業績變動原因:2019年度,國內法醫市場形勢複雜,競爭日趨激烈,受價格戰影響較大,同時國內經濟下行壓力加大,導致中德美聯產品整體市場價格下降;加之人力成本、生產成本不斷增加,產品毛利率同比有較大下降,2019年度中德美聯雖然營業收入穩步增長,但是淨利潤出現了下降。
3、2019年度,蘇豪逸明公司作為多肽原料藥企業,在終端藥價下降、原物料價格上漲的情況下,不斷提升現有產品質量、加大研發投入,該公司成本費用有所增加。在上述因素的影響下,蘇豪逸明2019年度銷售收入、淨利潤有所下降,與預期相比存在一定差距。
4、報告期內,公司繼續加大對新產品研發的投入,研發費用增長快速,一定程度上影響了利潤指標。
5、報告期內,非經常性損益對淨利潤的影響金額預計約為2100萬元,上年度同期非經常性損益對淨利潤的影響金額為-597.15萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.